ClinicalTrials.gg
Not yet recruitingNCT07483320Updated Sep 25, 2026

Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy

An interventional study of Platelet Rich Plasma and Extracorporeal Shockwave Therapy in Achilles Injuries Tendon, Achilles Tendinopathy (AT) and Achilles Tendinitis, Left Leg, sponsored by Spaulding Rehabilitation Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Sep 25, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Planned enrollment
913th of 2,564
100 · median 66
Started
2026
with 114 others
No phase
1,244 of 2,886
183 open now
Primary completion
2028-03
later than 291 of 392 live
Registered
2,820th of 2,886
by date

Among the 2,886 studies in Pain with a site in United States, this one is the 913th largest by planned enrollment of the 2,564 interventional ones that give a count, is one of 115 that started in 2026, is one of 1,244 with no phase, reaches primary completion later than 291 of the 392 other live ones, and was the 2,820th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

310 more — sign in →

All 315 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,886 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

Midportion Achilles tendinopathy is a common cause of pain and functional limitation in both athletes and the general population. Progressive tendon loading programs are considered first-line treatment but do not lead to satisfactory outcomes in all patients. Extracorporeal shockwave therapy (ESWT) and platelet-rich plasma (PRP) injections are commonly used interventions for refractory symptoms, yet evidence supporting their combined use is limited particularly in treating Achilles tendon disorders.

This randomized controlled trial will evaluate the effectiveness of a standardized exercise program alone or in combination with PRP injection, ESWT, or both therapies in active adults with midportion Achilles tendinopathy. Participants will be randomized to one of four treatment groups and followed for six months. The primary outcome will assess changes in Achilles tendon symptoms and function using the Victorian Institute of Sport Assessment-Achilles (VISA-A) score. Secondary outcomes will include patient-reported outcomes, physical function testing, ultrasound tendon structure measures, and gait biomechanics.

Read the detailed description

Midportion Achilles tendinopathy (Mid-AT) is characterized by pain, stiffness, and impaired function resulting from a failed tendon healing response. Progressive loading exercise programs such as the Silbernagel protocol represent the current standard treatment and provide meaningful improvement for many individuals. However, approximately 40% of patients continue to experience persistent symptoms despite rehabilitation.

Extracorporeal shockwave therapy (ESWT) and platelet-rich plasma (PRP) injections are increasingly used in clinical practice to address refractory symptoms. ESWT is proposed to stimulate tissue healing through mechanotransduction and has demonstrated improved outcomes when combined with exercise therapy in some studies. PRP contains concentrated autologous growth factors that may enhance tendon healing through stimulation of extracellular matrix production, angiogenesis, and collagen synthesis.

Despite increasing clinical use, there remains limited evidence evaluating the comparative or combined effects of PRP and ESWT in the treatment of Achilles tendinopathy. Furthermore, few trials have evaluated these therapies within a standardized rehabilitation framework.

The purpose of this randomized controlled trial is to evaluate the effectiveness of exercise therapy alone compared with exercise therapy combined with PRP injection, ESWT, or both interventions in individuals with chronic midportion Achilles tendinopathy. Participants will be randomized to one of four treatment groups: exercise with sham procedures (control), exercise plus PRP injection, exercise plus ESWT, or exercise combined with PRP and ESWT. Participants will be followed for six months to evaluate patient-reported outcomes, tendon structure using ultrasound, physical function testing, and gait biomechanics. This study aims to determine whether PRP, ESWT, or the combination of both treatments provide superior functional recovery compared with exercise-based rehabilitation alone.

03

Conditions studied

  • Achilles Injuries Tendon
  • Achilles Tendinopathy (AT)
  • Achilles Tendinitis, Left Leg
  • Achilles Tendinitis, Right Leg
  • Achilles Tendon Pain
  • Achilles Tendonitis

Keywords

  • PRP
  • platelet rich plasma
  • extracorporeal shockwave
  • focus shockwave
  • radial pressure waves
  • rehabilitation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years
  • Diagnosis of unilateral midportion Achilles tendinopathy
  • Symptoms present for more than 3 months
  • VISA-A score \<80 at baseline
  • Pre-injury physical activity level ≥3 on the Physical Activity Scale
  • Ability to participate in rehabilitation program

Exclusion criteria

Exclusion Criteria:

  • Symptoms present for less than 3 months
  • Prior PRP injection or ESWT treatment to the Achilles tendon within 3 months
  • Other lower extremity musculoskeletal injury affecting function
  • Symptomatic arthritis affecting the ankle or foot
  • Rheumatologic disease or connective tissue disorder
  • Coagulopathy or anticoagulant therapy affecting function
  • Neuropathy affecting pain perception
  • Known cardiac condition contraindicating treatment
  • Poorly controlled diabetes ( >9.0)
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Sham comparator
    Arm 1 - Control Exercise Therapy + Sham PRP + Sham Shockwave

    A sham PRP injection will be performed where the needle breaks the skin but does not fenestrate the tendon. The sham ESWT will include radial pressure waves and focused shockwaves delivered without the device turned on to deliver energy and audio recording. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.

    Device: Sham PRP · Device: Sham ESWT

  • Experimental
    Arm 2 - Exercise Therapy + Platelet-Rich Plasma (PRP) + Sham Shockwave

    PRP will be delivered around the tendon, sham ESWT will be issued. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.

    Device: Platelet Rich Plasma · Device: Sham ESWT

  • Experimental
    Arm 3 - Exercise Therapy + Extracorporeal Shockwave Therapy (ESWT) + Sham PRP

    Sham PRP will be delivered. Three sessions of ESWT will be delivered to the Achilles tendon. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.

    Device: Extracorporeal Shockwave Therapy · Device: Sham PRP

  • Experimental
    Arm 4 - Exercise Therapy + Platelet-Rich Plasma + Extracorporeal Shockwave Therapy

    PRP will be administered followed by three sessions of ESWT. Standard of care exercise program will be prescribed to participants with four stages to be performed during the study.

    Device: Platelet Rich Plasma · Device: Extracorporeal Shockwave Therapy

Interventions

  • DevicePlatelet Rich Plasma

    Participants randomized to PRP will receive a single ultrasound-guided injection of approximately 3 mL of neutrophil-poor platelet-rich plasma derived from autologous blood. Blood will be processed to concentrate platelets and the PRP will be injected adjacent to the Achilles tendon at the site of maximal pain.

  • DeviceExtracorporeal Shockwave Therapy

    Participants randomized to ESWT will receive three weekly treatment sessions. Focused shockwave therapy will deliver approximately 2000 shocks with gradual energy escalation, followed by radial shockwave therapy delivering approximately 3000 pulses to the Achilles tendon and 3000 pulses to surrounding musculature.

  • DeviceSham PRP

    A needle will be inserted but no injection will occur around the Achilles tendon

  • DeviceSham ESWT

    Both focused shockwave and radial pressure wave will be in contact with the skin, but the devices will not be active to deliver energy. An audio recording will provide noises similar to the machines operating.

06

What researchers measure

Primary outcomes

  1. Victorian Institute of Sport Assessment-Achilles (VISA-A)

    The VISA-A is an eight item questionnaire measures Achilles tendon pain and function, with scores ranging from 0 to 100 (higher scores indicating better function).

    Time frame: baseline, 8 weeks, 4 months, 6 months

Secondary outcomes

  1. PROMIS-29 Patient Reported Outcomes

    Change in PROMIS-29 domain scores evaluating physical function, pain interference, fatigue, sleep disturbance, anxiety, depression, and social participation.

    Time frame: Baseline, 8 weeks, 4 months, 6 months

  2. University of Wisconsin Running Injury and Recovery Index (UWRI)

    Running-specific recovery and functional ability measure for participants who run regularly.

    Time frame: baseline, 8 weeks, 4 months, 6 months

  3. Ultrasound Tendon Cross-Sectional Area

    Changes in Achilles tendon cross-sectional area measured by ultrasound at the site of maximal tendon thickness.

    Time frame: baseline, 6 months

  4. Heel Rise Test Endurance

    Total number of single-leg heel raises performed until fatigue or inability to maintain pace or same height.

    Time frame: baseline, 6 months

  5. Hop Test Pain

    Pain rating following completion of a standardized single-leg hop test of 20 repetitions.

    Time frame: baseline, 6 months

  6. Gait Biomechanics

    Changes in lower extremity biomechanics and symmetry during walking and running assessed using motion capture and instrumented treadmill analysis in those who elect to complete biomechanical assessment.

    Time frame: baseline, 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided — No identifiable information will be shared outside Mass General Brigham. We will consider publishing a limited deidentified data set at time of publication of our findings.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Mar 2028, 17 months later.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 17 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: start Aug 2026 → Oct 2026, primary completion Nov 2027 → Mar 2028 and completion May 2028 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2026
First posted
Mar 19, 2026
StartEst.
Oct 15, 2026was Aug 2026
Primary completionEst.
Mar 15, 2028was Nov 2027
CompletionEst.
Sep 30, 2028was May 2028
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Oct 15, 2026
Sep 25, 2026
Primary completion
Nov 30, 2027→Mar 15, 2028
Sep 25, 2026
Study completion
May 30, 2028→Sep 30, 2028
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Start date Aug 1, 2026→Oct 15, 2026
    Primary completion Nov 30, 2027→Mar 15, 2028
    Study completion May 30, 2028→Sep 30, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07483320
Collaborators
Storz Medical AG, Foundation for Physical Medicine and Rehabilitation
Responsible party
Adam Tenforde (Associate Professor, Harvard Medical School, Spaulding Rehabilitation Hospital) — Principal investigator
First posted
Mar 19, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Mar 15, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Sep 25, 2026

Study contacts

Sydney Karnovsky, MD
Contact
skarnovsky@mgb.org
(862) 216-8050
Adam S. Tenforde, MD
principal investigator · Spaulding Rehabiltaition Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion